Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EPS (Basic) (2016 - 2026)

Insight Molecular Diagnostics' EPS (Basic) history spans 6 years, with the latest figure at -$0.74 for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 67.83% to -$0.74 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.64, a 65.62% increase, with the full-year FY2025 number at -$1.65, up 64.59% from a year prior.
  • EPS (Basic) hit -$0.74 in Q4 2025 for Insight Molecular Diagnostics, down from -$0.34 in the prior quarter.
  • Over the last five years, EPS (Basic) for IMDX hit a ceiling of $4.56 in Q4 2022 and a floor of -$2.3 in Q4 2024.
  • Historically, EPS (Basic) has averaged -$0.37 across 5 years, with a median of -$0.32 in 2022.
  • The widest YoY moves for EPS (Basic): up 2782.35% in 2022, down 1133.33% in 2022.
  • Tracing IMDX's EPS (Basic) over 5 years: stood at -$0.17 in 2021, then surged by 2782.35% to $4.56 in 2022, then tumbled by 138.03% to -$1.73 in 2023, then tumbled by 32.62% to -$2.3 in 2024, then soared by 67.83% to -$0.74 in 2025.
  • Business Quant data shows EPS (Basic) for IMDX at -$0.74 in Q4 2025, -$0.34 in Q3 2025, and -$0.3 in Q2 2025.